Additional file 4: of A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Overview of treatment-related serious adverse events occurring by severity (n [%]). (DOC 49 kb)